Stoke Therapeutics filed a prospectus supplement to offer and sell up to $200 million of common stock under an existing at-the-market equity offering agreement with Cantor Fitzgerald. This filing updates the automatic shelf registration statement previously established in March 2026. The company operates in the biotechnology industry, focusing on developing treatments for genetic diseases.

Stoke Therapeutics reported second quarter 2026 financial results and provided business updates. The company generated $9.3 million in revenue, a decrease from $13.8 million in the prior year period, and incurred a net loss of $61.6 million, or $0.93 per share, compared to a net loss of $23.5 million previously. Research and development expenses rose to $49.5 million due to increased activities for zorevunersen. The company holds approximately $420 million in cash and marketable securities, funded by $354.3 million at quarter-end and $65.7 million from a subsequent ATM sale. Clinically, the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome completed enrollment of 162 patients, with data readout anticipated in Q3 2027. A pre-NDA meeting with the FDA is scheduled for H2 2026, and a rolling U.S. NDA submission is planned to initiate in Q1 2027. Additionally, dose escalation continues in the Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA). Stoke Therapeutics operates as a biotechnology company developing RNA medicines.

Stoke Therapeutics, Inc. announced the completion of patient enrollment for its Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, enrolling 162 patients across the U.S., U.K., and Japan. A Phase 3 data readout is expected in the third quarter of 2027, and the company plans to initiate a rolling New Drug Application (NDA) submission to the FDA in the first quarter of 2027. Stoke Therapeutics, Inc. is a biotechnology company developing potential disease-modifying treatments for genetic neurological disorders.